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Abstract 
Background: Enhanced advanced glycation end products deposition within myocardial tissue may cause diastolic 
dysfunction. However, whether this is related to left ventricular hypertrophy or inappropriate left ventricular mass 
remains unclear.
Methods: We prospectively enrolled 139 subjects at risk for cardiovascular diseases. We used echocardiography for 
measurements of left ventricular mass and cardiac systolic and diastolic functional parameters. An advanced glycation 
end product reader was applied for measurements of skin autofluorescence values. Comparisons of left ventricular 
mass and echocardiographic parameters between the higher and lower skin autofluorescence groups were analyzed.
Results: Compared with the lower skin autofluorescence group, left ventricular mass index and the ratio of observed 
left ventricular mass/predicted left ventricular mass (oLVM/pLVM) was significantly higher in the higher skin auto‑
fluorescence group (61.22 ± 17.76 vs. 47.72 ± 11.62, P < 0.01, 1.62 ± 0.38 vs. 1.21 ± 0.21, P < 0.01). After adjustment 
for potential confounding factors, skin autofluorescence was an independent factor for left ventricular mass index 
(β = 0.32, P < 0.01) and the ratio of oLVM/pLVM (β = 0.41, P < 0.01). Skin autofluorescence ≥2.35 arbitrary unit 
predicted left ventricular hypertrophy at a sensitivity of 58.8%, and a specificity of 73.0% (P < 0.01). Skin autofluo‑
rescence ≥2.25 arbitrary unit predicted inappropriate left ventricular mass at a sensitivity of 71.1%, and a specificity 
of 83.9% (P < 0.01). Skin autofluorescence was positively correlated with E/E′, an indicator for diastolic dysfunction 
(r = 0.21, P = 0.01).
Conclusions: Skin autofluorescence is a useful tool for detecting left ventricular hypertrophy, inappropriate left ven‑
tricular mass and diastolic dysfunction.
Keywords: Advanced glycation end product, Skin autofluorescence, Inappropriate left ventricular mass, Diastolic 
dysfunction
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Background
Increased left ventricular mass (LVM) may develop 
as a consequence of chronic pressure overload. When 
the growth of LVM exceeds its need to compensate for 
cardiac workload, it is defined as inappropriate LVM 
[1]. Clinically, inappropriate LVM has been proposed 
as an independent risk factor for adverse cardiovascu-
lar outcomes in hypertensive subjects [1–4]. Although 
the clinical significance of inappropriate LVM has been 
well validated, a clinically useful marker for predicting 
inappropriate LVM, especially in subjects at moder-
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Advanced glycation end products (AGEs) are mol-
ecules formed by a nonenzymatic reaction between a 
reducing sugar and an amine group of protein, or lipid, 
called “the Maillard reaction” [5]. Enhanced AGEs accu-
mulation throughout the skin, cardiac, renal, and vascu-
lar tissues can be found in aging, diabetic, or renal failure 
patients [5]. In cardiac tissue, the AGEs may covalently 
cross-link with extracellular matrix (ECM), such as col-
lagen, laminin, and elastin, which may lead to the devel-
opment of myocardial stiffness, impaired myocardial 
relaxation, and diastolic dysfunction [6–8]. In addition 
to their cross-link with ECM, AGEs could also stimulate 
the expression of ECM genes coding for type IV collagen, 
laminin [9]. Treatment with AGEs breaker (ALT-711) in 
Streptozocin-induced diabetic rats has also been demon-
strated in association with reduced left ventricular mass, 
reduced protein expression of collagen tissue growth fac-
tor and collagen III [10]. For these reasons, AGEs accu-
mulation may be associated with increased LVM. Skin 
autofluorescence (AF) is a simple, non-invasive method 
to measure the tissue accumulation of AGEs, and its 
accuracy has been validated [11]. In addition, skin AF has 
been validated as a useful tool for predicting long-term 
adverse cardiovascular outcomes in subjects of diabetes 
[12], and renal failure [13].
This study has thus been designed to test the hypoth-
esis that skin AF measurement could be a useful tool to 
detect left ventricular hypertrophy (LVH), or even, inap-
propriate LVM in subjects at risk for CV diseases.
Methods
Study design and subjects
We prospectively recruited 139 subjects at risk for CV 
diseases at the age between 40 and 80  years old whose 
condition were stable, and had regular medical visits to 
our outpatient department for over 1 year. The definition 
of risk for CV diseases included (1) at least two conven-
tional CV risk factors [family history of premature coro-
nary artery disease, male gender with an age ≥45 years, 
or female gender with an age  ≥50  years, hypertension, 
diabetes mellitus (DM), hyperlipidemia, and smoking]; 
(2) any history of ischemic heart disease (IHD), cerebro-
vascular disease or peripheral arterial occlusive disease 
(PAOD). The exclusion criteria included subjects with 
dementia, impaired conscious level, bed ridden status, 
any histories of psychiatric diseases, liver cirrhosis, end-
stage renal disease requiring renal replacement therapy, 
advanced stage of cancer, or alcoholism. Subjects with 
prior myocardial infarction, cardiac arrhythmia, cardio-
myopathy, or moderate-to-severe valvular heart diseases 
were also excluded. We obtained baseline demographic 
data by chart review and patients’ interview. Labora-
tory tests were all sampled within 3  months before the 
study enrollment. Body mass index (BMI) was defined 
as the body weight (g) divided by the square of body 
height (m2). DM was defined as a plasma level of glyco-
hemoglobin ≥6.5% or the use of hypoglycemic medica-
tions for over 6  months. Hypertension was defined as 
a series of at least three systolic blood pressure (SBP) 
measurements  ≥140  mmHg or diastolic blood pres-
sure (DBP) measurements  ≥90  mmHg at office or the 
use of anti-hypertensive medications for over 6 months. 
Hyperlipidemia was defined as a plasma level of total 
cholesterol >200 mg/dL, low-density lipoprotein choles-
terol >130 mg/dL, triglyceride >150 mg/dL, or the use of 
lipid-lowering medications for over 6 months. Estimated 
glomerular filtration rate (eGFR) (mL/min/1.73  m2), a 
proxy for renal function, was calculated according to 
the modification of diet in renal disease (MDRD) study 
equation. IHD was defined as the presence of angina 
symptoms with evidence of ischemia diagnosed by non-
invasive stress testing, or invasive coronary angiogra-
phy. Cerebrovascular disease was defined as any event of 
ischemic stroke or transient ischemic attack diagnosed by 
computed tomography or magnetic resonance imaging. 
PAOD was defined as an ankle-brachial index (ABI) <0.9 
further confirmed by non-invasive duplex ultrasound, 
computed tomography, or invasive peripheral angiog-
raphy. The institution’s ethics committee for research 
in human subjects has approved the study. (reference 
numbers: CMUH103-REC2-021). Informed consent was 
obtained from each patient, and the study protocol con-
forms to the ethical guidelines of the 1975 Declaration of 
Helsinki as reflected in a priori approval by the institu-
tion’s human research committee.
Echocardiography
All study subjects were instructed to rest for 30 min and 
blood pressure was measured thereafter by using a mer-
cury sphygmomanometer before the study. Then echo-
cardiography was performed in a dimly lit room with the 
study subjects in a partial left decubitus position. The 
methods of measuring echocardiographic parameters 
were in accordance with the recommendations from pre-
vious guidelines [14, 15]. In brief, left ventricular internal 
dimensions (LVID), septal and posterior wall thickness 
(SWT and PWT) were measured from the paraster-
nal long-axis window at the level of mitral valve leaflet 
tips by using M-mode echocardiography. From this, the 
observed LVM (oLVM) was calculated as follows [16]:
Left ventricular mass index (LVMI) was computed as 
normalization of LVM for height to the 2.7th power. Left 
LVM (g) = 0.8× {1.04[LVIDd+ PWTd+ SWTd)3]}
− (LVIDd3 + 0.6g
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ventricular hypertrophy (LVH) was defined as LVMI ≥51 
(g/m2.7) in men, and LVMI ≥47 (g/m2.7) in women [17]. 
Left ventricular volumes at end-diastolic (EDV) and end-
systolic phase (ESV) were measured using the biplane 
method of disks (modified Simpson’s rule). From this, 
the stroke volume was generated and the left ventricular 
ejection fraction (LVEF) was calculated as follows:
Theoretical individual LVM value predicted for sex, 
body size and cardiac workload was calculated as follows:
where male  =  1, and female  =  2. Appropriateness of 
LVM was defined as the ratio of oLVM indexed to the 
pLVM. The ratio of oLVM divided by pLVM was defined 
as inappropriate when there was an excess of >28% from 
the predicted value (oLVM/pLVM >128%) [4].
To further investigate the diastolic function, pulse-wave 
Doppler echocardiography was performed by placing a 
sample volume (1–3  mm) between the tips of the mitral 
valve in the apical four-chamber view during diastole [15]. 
Peak E (early diastolic) and A (late diastolic) mitral inflow 
velocities, the E/A ratio, deceleration time (DT) of early 
mitral filling velocity were derived. By applying pulsed-wave 
tissue Doppler echocardiography in the apical four-chamber 
view to acquire mitral annular velocity at the septal portion, 
E′ (early diastolic) annular velocity and A′ (late diastolic) 
annular velocity at the septal portion were derived. Thus, 
the E/E′, a proxy for mitral filling pressure, was generated.
Skin AF as an estimation for tissue AGEs accumulation
The amount of skin AGE accumulation was estimated 
by measuring skin AF with an AGE reader (DiagnOptics 
Technologies BV, Groningen, the Netherlands). The AGE 
reader uses the fluorescence properties of some AGEs 
to estimate the accumulation of AGEs in skin. The AGE 
reader illuminated an ultraviolet light with wavelengths 
between 300 and 420 nm. The emitted light with wave-
lengths between 420 and 600 nm, and the reflected exci-
tation light with wavelengths between 300 and 420  nm 
were measured with a spectrometer. Skin AF was meas-
ured as the ratio of the average light intensity between 
the emitted light and the reflected excitation light, 





= cuff systolic BP× stroke volume× 0.0144;
Predicted LVM (pLVM)









multiplied by 100, and expressed as arbitrary units (AU). 
The protocol of skin AF measurement has been described 
elsewhere [11]. The intra-individual error percentage of 
repeat skin AF measurements taken within a day was 
5.03%, and for seasonal variation was 5.87% [11].
Statistical methods
Differences of continuous variables and categorical vari-
ables were compared with Student’s unpaired t test, and the 
Chi square test, respectively. The relations between skin AF, 
appropriateness of LVM, and echocardiographic param-
eters were analyzed with Pearson’s correlation test. Univari-
ate linear regression analysis was applied to evaluate factors 
associated with LVMI and appropriateness of LVM. Factors 
with P value <0.05 were selected and included in the step-
wise multivariate linear regression analysis to determine 
independent factors. Receiver operating characteristic 
(ROC) curve analysis was applied to determine the optimal 




All study subjects were divided into two groups accord-
ing to the measured skin AF above or below the median 
value. Table  1 displays the baseline demographics and 
the comparisons between the higher skin AF group and 
the lower skin AF group. Compared with the lower skin 
AF group, the higher one was significantly older, and had 
higher proportions of IHD, and lower DBP. In the higher 
skin AF group, the proportion of inappropriate LVM is 
significantly higher than in the lower skin AF group (86.8 
vs. 33.8%; χ2 P < 0.01). The results are in Fig. 1a, b.
Echocardiographic parameters
Comparisons of echocardiographic parameters between 
the higher skin AF group and the lower skin AF group 
are displayed in Table  2. Compared with the lower skin 
AF group, the higher one has significantly lower LVEF, 
indicating a poorer systolic performance. In addition, the 
higher skin AF group had significantly higher left atrial 
(LA) diameter, lower early diastolic peak velocity at sep-
tal portion of mitral annulus, and higher E/E′ ratio, indi-
cating more diastolic dysfunction. Both the LVMI and the 
ratio of oLVM indexed to the pLVM were significantly 
higher in the higher skin AF group than in the lower skin 
AF group.
Skin autofluorescence as an independent factor 
for appropriateness of left ventricular mass
Results from the univariate linear regression analysis 
investigating factors associated with LVMI are displayed 
in Additional file 1. Age, BMI, skin AF, SBP, PP, smoking, 
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stroke, IHD, PAOD, eGFR, LA diameter, A, E/A ratio, E′, 
A′, E/E′ were associated with LVMI. Stepwise multivari-
ate linear regression analysis revealed that skin AF was 
significantly associated with LVMI, independent from 
other covariates including PAOD, BMI, PP, A′, and eGFR. 
An increase of 1 arbitrary unit of skin AF explained an 
increase of 10.67 g/m2.7 of LVMI (Table 3).
A further investigation to determine factors associated 
with the ratio of oLVM indexed to the pLVM is summa-
rized in Additional file  2. Age, skin AF, DBP, smoking, 
IHD, PAOD, eGFR, LVEF, LA diameter, A, E/A, E′, A′, 
and E/E′ were associated with the ratio of oLVM indexed 
to pLVM. Stepwise multivariate linear regression analy-
sis revealed that skin AF was significantly associated with 
the ratio of oLVM indexed to pLVM, independent from 
A′, LVEF, PAOD and E/A. An increase of 1 arbitrary unit 
of skin AF explained an increase of 0.3 of the ratio of 
oLVM indexed to pLVM.
Skin AF as a useful tool for predicting LVH 
and inappropriate LVM
The receiver operating characteristic (ROC) curve was 
used to determine the optimal cut-off value for predict-
ing inappropriate LVM (Fig. 2a) and LVH (Fig. 2b). Skin 
AF ≥2.25 AU predicted inappropriate LVM at a sensitiv-
ity of 71.1%, and a specificity of 83.9% with an AUC of 
0.79 (95% CI 0.71–0.87, P < 0.01). Skin AF ≥2.35 AU pre-
dicted LVH at a sensitivity of 58.8%, and a specificity of 
73.0% with an area under the curve (AUC) of 0.67 (95% 
CI 0.57–0.76, P < 0.01).
Table 1 Baseline demographics of the study group
Skin AF skin autofluorescence, AU arbitrary unit, BMI body mass index, SBP 
systolic blood pressure, DBP, diastolic blood pressure, PP pulse pressure, DM 
diabetes mellitus, OHA oral hypoglycemic agent, RI regular insulin, IHD ischemic 
heart disease, GFR glomerular filtration rate, CCBs calcium channel blockers, 
ACEIs angiotensinogen converting enzyme inhbitors, ARBs angiotensin II type I 
receptor blockers
Skin AF ≤2.2  
(n = 71)
Skin AF >2.2  
(n = 68)
P value
Age (years) 61.34 ± 11.34 66.57 ± 8.38 0.01
Gender (M/F) 41/30 43/25 0.51
Skin AF (A.U.) 1.90 ± 0.27 2.71 ± 0.31 0.01
BMI (kg/m2) 26.50 ± 3.86 26.05 ± 3.25 0.74
SBP (mmHg) 142.36 ± 14.83 139.06 ± 16.81 0.22
DBP (mmHg) 80.80 ± 13.57 75.41 ± 9.46 0.01
PP (mmHg) 61.92 ± 12.70 63.94 ± 14.64 0.39
Hypertension, n (%) 59 (83.10) 57 (83.82) 0.91
DM, n (%) 0.06
 None, n (%) 50 (70.42) 40 (58.82)
 OHA, n (%) 20 (28.17) 21 (30.88)
 RI, n (%) 1 (1.41) 7 (10.29)
Hyperlipidemia, 
n (%)
57 (80.28) 52 (76.47) 0.59
Stroke, n (%) 3 (4.23) 7 (10.29) 0.17
IHD, n (%) 9 (12.68) 21 (30.88) 0.01
PAOD, n (%) 1 (1.41) 1 (1.47) 0.98
eGFR (mL/min/1.73 
m2)
66.64 ± 17.77 62.06 ± 22.73 0.19
Antiplatelets, n (%) 48 (67.61) 43 (63.24) 0.59
β‑Blockers, n (%) 25 (35.21) 34 (50.00) 0.08
CCBs, n (%) 29 (40.85) 33 (48.53) 0.36
ACEIs/ARBs, n (%) 49 (69.01) 43 (63.24) 0.47
Statins, n (%) 40 (56.34) 41 (60.29) 0.64
Smoking 0.06
 Never, n (%) 55 (77.46) 40 (58.82)
 Ever, n (%) 10 (14.08) 19 (27.94)




        (66.2%) 
Inappropriate LVM 
        (33.8%)
Inappropriate LVM
        (86.8%)
Appropriate LVM
      (13.2%)
Fig. 1 Proportions of inappropriate left ventricular mass in a lower 
skin autofluorescence group and in b higher skin autofluorescence 
group are depicted
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Association between skin AF and myocardial performance
We further tested whether measurements of skin AGEs 
accumulation could be associated with myocardial per-
formance. In Fig.  3a and b, skin AF is associated with 
E/E′ (r = 0.21; P = 0.01), but not with LVEF (r = −0.16; 
P = 0.07).
Relation between LVM and myocardial performance
In Table  4, both increased LVM and ratio of oLVM 
indexed to pLVM are significantly correlated with 
reduced E/A ratio, E′, A′ and increased LA diameter, E/E′, 
indicative of diastolic dysfunction. Only increased ratio 
of oLVM indexed to pLVM is correlated with reduced 
LVEF, indicative of systolic dysfunction.
Comparisons between appropriate LVM group 
and inappropriate LVM group
Comparisons of baseline demographic and echocardio-
graphic parameters between appropriate LVM and inap-
propriate LVM groups were analyzed, and the result is 
displayed in Table 5. Compared to the appropriate LVM, 
the inappropriate LVM has significantly higher propor-
tions of female sex, IHD, and increased skin AF, LVMI, 
LA diameter, E/E′. In addition, the inappropriate LVM 
has significantly lower DBP, LVEF, E′, and A′, than the 
appropriate LVM. Difference in measured skin AF values 
between the two groups was further depicted in Fig. 4.
Considering the potential confounding effect of LVH, 
we further divided the study subjects into two subgroups 
according to the presence of LVH. The result is displayed 
in Table  6. In subjects without LVH, an increase in the 
ratio of oLVM/pLVM shows a trend, though not statisti-
cally significant, toward a reduced LVEF.
Discussion
In this study, we proposed that skin AF could predict 
LVH and inappropriate LVM. In addition, increased skin 
AF value is associated with elevated mitral filling pres-
sure, a marker for diastolic dysfunction.
Skin AF as a marker for subclinical microvascular 
and macrovascular diseases
The application of skin AF as a marker for microvascu-
lar and macrovascular diseases in subjects with diabetes 
Table 2 Echocardiographic parameters of the study group
Skin AF skin autofluorescence, LVEF left ventricular ejection fraction, LA left 
atrium, E early diastolic peak velocity, A late diastolic peak velocity, E′ early 
diastolic peak velocity at septal portion of mitral annulus, A′ late diastolic peak 
velocity at septal portion of mitral annulus, SW septal wall, DT deceleration time, 
LVMI left ventricular mass index, oLVM observed left ventricular mass, pLVM 
predicted left ventricular mass
Skin AF ≤2.2 Skin AF >2.2 P value
LVEF (%) 68.80 ± 7.20 65.82 ± 8.11 0.02
LA diameter (mm) 35.34 ± 4.01 38.91 ± 4.72 0.01
E (cm/s) 74.88 ± 15.62 74.37 ± 19.16 0.86
A (cm/s) 87.94 ± 22.28 93.80 ± 20.60 0.11
E/A ratio 0.89 ± 0.26 0.82 ± 0.24 0.11
E’(SW) (cm/s) 7.54 ± 2.13 6.17 ± 1.84 0.01
A’(SW) (cm/s) 10.11 ± 2.08 9.44 ± 2.10 0.06
E/E’ ratio 10.73 ± 3.81 12.90 ± 4.50 0.01
DT (ms) 212.44 ± 42.20 227.85 ± 51.90 0.06
LVMI (g/m2.7) 47.72 ± 11.62 61.22 ± 17.76 0.01
oLVM/pLVM 1.21 ± 0.21 1.62 ± 0.38 0.01
Table 3 Stepwise multivariate linear regression analysis to investigate independent factors associated with (a) increased 
left ventricular mass and (b) observed left ventricular mass/predicted left ventricular mass
SE. standard error, Skin AF skin autofluorescence, A.U. arbitrary unit, PAOD peripheral arterial occlusive disease, BMI body mass index, PP pulse pressure, A′ late diastolic 
peak velocity at septal portion of mitral annulus, GFR glomerular filtration rate, LVEF left ventricular ejection fraction, E early diastolic peak velocity, A late diastolic 
peak velocity
Unstandardized coefficient B SE Standardized coefficient β P value
(a)
 Skin AF (A.U.) 10.67 2.32 0.32 <0.01
 PAOD 31.35 9.54 0.23 <0.01
 BMI 1.16 0.32 0.25 <0.01
 PP 0.23 0.09 0.19 <0.01
 A′ −1.61 0.55 −0.21 <0.01
 eGFR −0.14 0.06 −0.17 0.02
(b)
 Skin AF (A.U.) 0.30 0.05 0.41 <0.01
 A′ −0.04 0.01 −0.24 <0.01
 LVEF −0.01 0.003 −0.20 <0.01
 PAOD 0.53 0.21 0.17 0.01
 E/A −0.23 0.10 −0.16 0.03
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or CKD has been proposed. Cho et al. proposed signifi-
cantly higher skin AF in young adolescents of type 1 dia-
betes with retinopathy than those without retinopathy 
[18]. Higher skin AF associated with endothelial dys-
function [19] and arterial pulse wave velocity [20] has 
been described in subjects with end-stage renal failure. 
Recently, Sell et  al. proposed skin collagen fluorophore 
LW-1 to be a useful marker for the subclinical macrovas-
cular disease in patients with type 1 diabetes. They sug-
gested that LW-1 level is significantly correlated with skin 
intrinsic fluorescence (SIF) level, a surrogate marker for 
tissue AGEs accumulation, and higher skin LW-1 level is 
associated with increased intima-media thickness (IMT) 
and LVM. However, in their study, the SIF level is not sig-
nificantly correlated with LVM, which is contradictory to 
our result [21]. The discrepancy is possibly explained by 
the different methods of measuring tissue AGEs accumu-
lation, calculating LVM, and different study populations 
with respect to ethnicity, age-distribution, and baseline 
comorbidities.
Rationale of tissue AGEs accumulation in relation 
to inappropriate LVM
Previous studies have suggested that chronic kid-






























AUC: 0.67; P< 0.01
Fig. 2 Receiver operating curves (ROC) of skin autofluorescence 
(AF) for predicting a inappropriate left ventricular mass and b left 






































r= 0.21; P= 0.01
Fig. 3 Correlation between skin autofluorescence and echocardio‑
graphic functional parameters are analyzed and displayed. a Skin 
autofluorescence is not significantly correlated with left ventricular 
systolic function. b Skin autofluorescence is negatively correlated 
with E/e′ ratio, a marker for diastolic function
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LVM [22–25]. However, the possible explanation for 
this association is not clear. AGEs are increased in 
subjects with chronic kidney disease due to increased 
oxidative stress, and decreased renal excretion [26]. A 
small scale clinical trial also observed that treatment 
with AGEs breaker may improve left ventricular dias-
tolic function and LVM regression [27]. Therefore, 
we hypothesized that AGEs might be related to LVM 
growth. Makulska et  al. [28] investigated the associa-
tion between skin AF and cardiovascular risk and pro-
posed that skin AF was significantly correlated with 
LVM in children with chronic kidney disease stage 
2–5. However, whether the increased LVM is inappro-
priate is not clear. Our study suggest that the amount 
of skin AGEs deposition is not only associated with 
LVH, but also with the extent of LVM growth exceed-
ing its physiological need.
Factors determining left ventricular mass
Increased hemodynamic load, body size, and gender are 
key factors for LVM growth. The adaptive response is 
used to protect myocardium from excessive wall stress, 
providing sufficient nutrients to body tissue by maintain-
ing or increasing cardiac output [29]. However, in some 
cases, the LVM may grow beyond the compensatory 
need and become inappropriate. This indicates that other 
factors may be involved in the abnormal LVM growth, 
such as genetic polymorphism [30], neurohormones 
[31], and cytokine [32]. Our study suggests that AGEs 
are related to inappropriate LVM. AGE-stimulated ECM 
gene expression and deposition might partially explain its 
association with abnormally increased LVM [9].
Higher predictive value of skin AF in detecting 
inappropriate LVM than detecting LVH
Our study demonstrated that skin AF had higher sensi-
tivity and specificity in detecting inappropriate LVM than 
in detecting LVH. In our study, over eighty percent of 
the study population have chronic hypertension. There-
fore, some LVH may be an appropriate response to the 
increased hemodynamic load.
Tissue AGEs accumulation in relation to impaired 
myocardial performance
In Table  2, increased skin AF value is associated with 
increased LA diameter, elevated E/E′, and reduced E′, 
indicating increased LA pressure and impaired relaxa-
tion. This suggests that skin AF could be a useful marker 
to detect diastolic dysfunction. At least 3 possible expla-
nations to support this idea: first, AGEs may cross-link 
with type IV collagen, elastin to increase ventricular stiff-
ness; second, AGEs may impair myocardial calcium han-
dling and lead to diastolic dysfunction [33]; third, AGEs 
may stimulate the excretion of TGF-β, thus increasing 
the ECM [9], and myocardial fibrosis. However, our data 
suggests that skin AF value is not associated with LVEF. 
This required further evaluation. A previous study has 
proposed that treatment with AGEs breaker for 36 weeks 
can neither improve clinical symptoms, nor myocardial 
function in the setting of systolic HF [34]. Our findings 
are in line with previous observations that tissue AGEs 
deposition may influence myocardial diastolic perfor-
mance, rather than systolic dysfunction.
Association between inappropriate LVM and myocardial 
dysfunction
In Table  4, an increased ratio of oLVM/pLVM is asso-
ciated with decreased LVEF, E/A ratio, E′, A′, and 
increased, E/E′. This implies that there is a relationship 
between inappropriate LVM and cardiac functional 
abnormalities, a finding accords with previous findings 
[35–37].
In Table  6, the ratio of oLVM/pLVM shows a trend 
toward an inverse association with LVEF in the setting of 
non-LVH subgroup. Mureddu et al. proposed that in the 
setting of chronic hypertension, subjects without LVH, 
but with inappropriate LVM, have a significantly lower 
cardiac index, and reduced left ventricular mid-wall 
shortening compared to subjects with appropriate LVM 
[38]. Our data correspond to their findings. The MAVI 
study indicated that in the non-LVH subgroup analysis, 
subjects with inappropriate LVM still had a worse prog-
nosis compared with subjects with appropriate LVM [1]. 
The inappropriate LVM-related cardiac functional abnor-
malities may provide some explanations.
Table 4 Correlation analysis between  oLVM/pLVM ratio, 
LVMI, and echocardiographic parameters
oLVM/pLVM observed left ventricular mass/predicted left ventricular mass, LVMI 
left ventricular mass index, LVEF left ventricular ejection fraction, LA left atrium, 
E early diastolic peak velocity, A late diastolic peak velocity, E′ early diastolic 
peak velocity at septal portion of mitral annulus, A′ late diastolic peak velocity at 
septal portion of mitral annulus, DT deceleration time
oLVM/pLVM LVMI
r P value r P value
LVEF −0.28 <0.01 −0.13 0.12
LA diameter 0.31 <0.01 0.33 <0.01
E −0.03 0.72 −0.03 0.74
A 0.21 0.01 0.18 0.03
E/A −0.20 0.02 −0.20 0.02
E′ −0.32 <0.01 −0.33 <0.01
A′ −0.31 <0.01 −0.24 <0.01
E/E′ 0.29 <0.01 0.29 <0.01
DT 0.16 0.06 0.12 0.17
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Study limitations
First, because this is an observational case–control study, 
we could only establish an association between tissue 
AGEs accumulation and inappropriate LVM. We could 
not provide any evidence of causal effect. Second, because 
we only enrolled subjects with a moderate to high risk 
for cardiovascular diseases, our study results cannot be 
generalized to other populations. Third, although we 
measured the subjects’ blood pressure before the echo-
cardiography study in order to calculate the predicted 
LVM, this single “office” blood pressure value may not 
represent the chronic wall stress imposed on the left 
ventricle. Whether ambulatory blood pressure monitor-
ing could be more representative requires further valida-
tion. Fourth, skin AF could only estimate the amount of 
tissue AGEs with fluorescent properties. Those without 
Table 5 Comparisons of baseline demographics and echocardiographic parameters between appropriate and  inappro-
priate left ventricular mass
LVM left ventricular mass, M male, F female, Skin AF skin autofluorescence, A.U. arbitrary unit, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood 
pressure, PP pulse pressure, DM diabetes mellitus, OHA oral hypoglycemic agent, RI regular insulin, IHD Ischemic heart disease, PAOD peripheral arterial occlusive 
disease, LVMI left ventricular mass index, GFR glomerular filtration rate, CCBs calcium channel blockers, ACEIs angiotensinogen converting enzyme inhbitors, ARBs 
angiotensin II type I receptor blockers, LVEF left ventricular ejection fraction, LA left atrium, E early diastolic peak velocity, A late diastolic peak velocity, E′ early diastolic 
peak velocity at septal portion of mitral annulus, A′ late diastolic peak velocity at septal portion of mitral annulus, SW septal wall, DT deceleration time
Appropriate LVM (n = 56) Inappropriate LVM (n = 83) P value
Age (years) 61.73 ± 11.55 65.36 ± 9.16 0.052
Gender (M/F) 40/16 44/39 0.03
Skin AF (A.U.) 2.03 ± 0.42 2.47 ± 0.46 <0.01
BMI (kg/m2) 26.57 ± 3.61 26.09 ± 3.55 0.44
SBP (mmHg) 143.59 ± 13.66 138.82 ± 17.00 0.08
DBP (mmHg) 81.60 ± 12.72 75.84 ± 10.98 <0.01
PP (mmHg) 62.62 ± 14.42 63.10 ± 13.22 0.84
Hypertension n (%) 49 (87.50) 67 (80.72) 0.29
DM, n (%) 0.20
 None, n (%) 36 (64.29) 54 (65.06)
 OHA, n (%) 19 (33.93) 22 (26.51)
 RI, n (%) 1 (1.78) 7 (8.43)
Hyperlipidemia, n (%) 41 (73.21) 68 (81.92) 0.22
Stroke, n (%) 2 (3.57) 8 (9.64) 0.18
IHD, n (%) 7 (12.50) 23 (27.71) 0.03
PAOD, n (%) 0 (0) 2 (2.41) 0.24
LVMI (g/m2.7) 44.56 ± 9.28 60.91 ± 16.83 <0.01
eGFR (mL/min/1.73 m2) 67.17 ± 15.76 62.53 ± 22.92 0.16
Antiplatelets, n (%) 35 (62.50) 56 (67.47) 0.55
β‑Blockers, n (%) 21 (37.50) 38 (45.78) 0.33
CCBs, n (%) 28 (50.00) 34 (40.96) 0.29
ACEIs/ARBs, n (%) 42 (75.00) 50 (60.24) 0.07
Statins, n (%) 30 (53.57) 51 (61.45) 0.36
Smoking 0.21
 Never, n (%) 43 (76.79) 52 (62.65)
 Ever, n (%) 9 (16.07) 20 (24.10)
 Active, n (%) 4 (7.14) 11 (13.25)
LVEF (%) 69.27 ± 8.16 66.04 ± 7.26 0.02
LA diameter (mm) 35.78 ± 4.20 37.98 ± 4.85 <0.01
E (cm/s) 73.31 ± 14.73 75.52 ± 18.99 0.47
A (cm/s) 88.13 ± 17.26 92.61 ± 24.02 0.23
E/A ratio 0.86 ± 0.26 0.85 ± 0.25 0.80
E′ (SW) (cm/s) 7.44 ± 2.11 6.49 ± 2.02 <0.01
A′ (SW) (cm/s) 10.35 ± 1.93 9.40 ± 2.15 <0.01
E/E′ ratio 10.65 ± 3.76 12.56 ± 4.47 <0.01
DT (ms) 220.09 ± 38.58 219.91 ± 53.14 0.98
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fluorescent properties could not be measured by skin AF. 
However, a previous study has established an association 
between skin AF and the amounts of skin deposition of 
both fluorescent and non-fluorescent AGEs [11]. Fifth, 
low vitamin D status has been linked to left ventricular 
hypertrophy [39], and elevated skin AF is associated with 
low serum vitamin D level in subjects with type 2 DM 
[40]. In our study, we cannot provide the subjects’ serum 
vitamin D level, which could be a potential confounding 
factor. Sixth, we used skin AF value as a surrogate marker 
for skin AGEs accumulation. We did not provide an evi-
dence that skin AF value could reflect the amount of 
myocardial AGEs deposit. However, previous study has 
reported a close association between skin AF values and 
tissue AGEs levels of atrial appendage [41].
Conclusions
We proposed that skin AF value is a useful marker for 
predicting LVH, and inappropriate LVM and diastolic 
dysfunction in subjects at risk for cardiovascular dis-
eases. Tissue AGEs accumulation might play some role in 
LVM growth exceeding its physiological need.
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Fig. 4 Comparisons of skin autofluorescence values between the 
appropriate left ventricular mass and inappropriate left ventricular 
mass are analyzed and depicted
Table 6 Correlation analysis between  oLVM/pLVM ratio 
and  echocardiographic parameters stratified according 
to the presence of LVH
oLVM/pLVM observed left ventricular mass/predicted left ventricular mass, LVH 
left ventricular hypertrophy, LVEF left ventricular ejection fraction, LA left atrium, 
E early diastolic peak velocity, A late diastolic peak velocity, E′ early diastolic 
peak velocity at septal portion of mitral annulus, A′ late diastolic peak velocity at 
septal portion of mitral annulus, DT deceleration time
Non-LVH (n = 59) LVH (n = 80)
r P value r P value
LVEF −0.24 0.06 −0.34 <0.01
LA diameter 0.11 0.39 0.24 0.03
E −0.08 0.55 0.01 0.97
A 0.34 <0.01 0.02 0.85
E/A −0.23 0.08 −0.01 0.90
E′ −0.18 0.17 −0.25 0.03
A′ −0.15 0.27 −0.32 <0.01
E/E′ 0.10 0.46 0.27 0.02
DT −0.03 0.81 0.13 0.26
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